이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

치료 효과를 위한 다양한 제제를 조사하는 만성 신장 질환 적응형 플랫폼 시험 (CAPTIVATE)

2026년 9월 29일 업데이트: The George Institute

CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD).

CAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people develop kidney failure.

CAPTIVATE provides a research platform that allows many treatment-related questions to be answered within a common trial set-up.

CAPTIVATE includes multiple domains examining different therapies for CKD. Participants may enrol in one or more domains and domains will be added and closed over time. The platform operates under a core protocol with each domain described in a domain specific appendix.

연구 개요

상세 설명

Chronic kidney disease (CKD) affects over 800 million people globally and is projected to be the 5th most common cause of death by 2040. CKD progresses to kidney failure, increases the risk of early death, heart disease, and leads to a poorer quality of life.

Current treatments do not entirely remove the risk of kidney failure in people with CKD. To improve the outcomes of people with CKD, it is crucial to find the best treatment or combination of treatments that can slow CKD progression. CAPTIVATE aims to address this need.

CAPTIVATE has been designed to test multiple treatments within a common research platform. This design is more efficient and will lead to a shorter time for patients to receive effective treatments. The trial is 'eternal', which means that participants will continue to be recruited for many years until the trial is finally wound up. It is also 'adaptive', providing the flexibility to add new treatments, or remove those that are not working.

Participants can participate in more than one treatment at the same time or at different times. Participants receive each study treatment for 2 years. For each treatment, participants are followed up at study visits that occur at approximately one month, 3 months, 6 months, 12 months, 18 months and 2 years after starting treatment. A final study visit occurs one month after the end of the 2-year treatment phase. Information collected at study visits include blood and urine test results, safety assessments and treatment adherence. Information about the overall health status of each participant is collected every 5 years.

연구 유형

중재적

등록 (추정된)

2000

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Auckland, 뉴질랜드, 1023
        • 모병
        • Auckland City Hospital
        • 연락하다:
          • Dr Helen Pilmore
      • Auckland, 뉴질랜드, 2025
        • 모병
        • Aotearoa Clinical Trials Trust, Middlemore Hospital
        • 연락하다:
          • Kalpa Jayanatha
      • Auckland, 뉴질랜드, 0620
        • 모병
        • Health New Zealand, Te Whatu Ora Waitemata, North Shore Hospital
        • 연락하다:
          • Ashik Hayat
      • Dunedin, 뉴질랜드, 9016
        • 모병
        • 201 Great King Street, Central Dunedin, Dunedin 9016, New Zealand
        • 연락하다:
          • John Schollum
      • Palmerston North, 뉴질랜드, 4442
        • 모병
        • Midcentral - Palmerston North Hospital
        • 연락하다:
          • Dr Curtis Walker
      • Whangarei, 뉴질랜드, 0148
        • 모병
        • Private Bag 9742 Maunu Road, Horahora, Whangārei 0148, New Zealand
        • 연락하다:
          • Adam Mullan
    • Hawkes Bay
      • Hastings, Hawkes Bay, 뉴질랜드, 4120
        • 모병
        • Health New Zealand, Te Whatu Ora Te Matau a Maui, Hawke's Bay Hospital
        • 연락하다:
          • Hussain Allawati
      • Colombo, 스리랑카, 00700
        • 모병
        • National Hospital of Sri Lanka
        • 연락하다:
          • Dr Mathu Selvarajah
      • Kandy, 스리랑카, 20000
        • 모병
        • Kandy National Hospital
        • 연락하다:
          • Dr Nishantha Nanayakkara
      • Kurunegala, 스리랑카
        • 모병
        • Kurunegala Teaching Hospital
        • 연락하다:
          • Dr Premil Rajakrishnan
      • Nugegoda, 스리랑카, 10250
        • 모병
        • Sri Jayewardenepura General Hospital
        • 연락하다:
          • Dr Harshani Perera
      • Peradeniya, 스리랑카, 20400
        • 모병
        • Peradeniya Teaching Hospital
        • 연락하다:
          • Dr Rajitha Abeysekera
      • Ragama, 스리랑카, 11010
        • 모병
        • Colombo North Teaching Hospital
        • 연락하다:
          • Dr Nalaka Herath
    • Northern Province
      • Jaffna, Northern Province, 스리랑카, 4000
        • 모병
        • Jaffna Teaching Hospital
        • 연락하다:
          • Dr. Brammah Thangarajah
    • Polonnaruwa
      • Colombo, Polonnaruwa, 스리랑카, 51000
        • 모병
        • National Nephrology Specialized Hospital
        • 연락하다:
          • Dr Naseef Thaseem
    • Western Province
      • Dehiwala, Western Province, 스리랑카, 10290
        • 모병
        • University Hospital, Kotelawala Defence University
        • 연락하다:
          • Dr Dilukshi Pilapitiya
    • Barcelona
      • Badalona, Barcelona, 스페인, 08916
        • 모집하지 않고 적극적으로
        • Hospital Germans Trias i Pujol
      • Horta-Guinardó, Barcelona, 스페인, 08035
        • 모병
        • Vall d'Hebron University Hospital
        • 연락하다:
          • Dr Maria Jose Soler Romeo
    • Espana
      • Valencia, Espana, 스페인, 46010
        • 모병
        • Hospital Clinico Universitario València (INCLIVA)
        • 연락하다:
          • Prof Jose Luis Gorriz Teruel
      • Dehradun, 인도, 248001
        • 아직 모집하지 않음
        • Max Superspeciality Hospital, Dehradun
        • 연락하다:
          • Puneet Arora
      • Ghaziabad, 인도, 201012
        • 모병
        • Max Superspecialty Hospital, Ghaziabad
        • 연락하다:
          • Manoj Kumar Singhal
      • Puducherry, 인도, 607403
        • 모병
        • Aarupadai Veedu Medical College & Hospital (AVMCH), Puducherry
        • 연락하다:
          • Venkatesh A
    • Andhra Pradesh
      • Visakhapatnam, Andhra Pradesh, 인도, 530045
        • 모병
        • Gitam Institute of Medical Sciences and Research
        • 연락하다:
          • Murty Mandapaka
    • Bihar
      • Patna, Bihar, 인도, 800001
        • 모병
        • Patna Medical College and Hospital
        • 연락하다:
          • Harsh Vardhan
    • Chhattisgarh
      • Raipur, Chhattisgarh, 인도, 492002
        • 모병
        • DKS Super Speciality Hospital, Raipur
        • 연락하다:
          • Varun Agrawal
    • Dehradun
      • Dehradun, Dehradun, 인도, 248001
        • 모병
        • Mysore Medical College
        • 연락하다:
          • Puneet Arora
    • Gujarat
      • Ahmedabad, Gujarat, 인도, 380025
        • 모병
        • GCS Medical College, Hospital & Research Centre
        • 연락하다:
          • Suvika Patel
      • Vadodara, Gujarat, 인도, 390007
        • 모병
        • Aman Hospital & Research Center Vadodara
        • 연락하다:
          • Aman Khanna
    • Karnataka
      • Mangaluru, Karnataka, 인도, 575002
        • 모병
        • Father Muller Medical College Hospital
        • 연락하다:
          • Manjunath Kulkarni
    • Kerala
      • Meppādi, Kerala, 인도, 673511
        • 모병
        • Dr Moopen's Medical College
        • 연락하다:
          • Aneesh Basheer
    • Madhya Pradesh
      • Indore, Madhya Pradesh, 인도
        • 모병
        • CARE-CHL Hospital
        • 연락하다:
          • Isha Tiiwari
    • Tamil Nadu
      • Chennai, Tamil Nadu, 인도, 600024
        • 모병
        • Medway Hospital
        • 연락하다:
          • Shivakumar Dakshinamoorthy
    • Telangana
      • Hyderabad, Telangana, 인도, 500084
        • 모병
        • Yashoda Hospital Hitec City
        • 연락하다:
          • Mahesh Kota
      • Hyderabad, Telangana, 인도
        • 모병
        • Apollo Hospitals
        • 연락하다:
          • Haresh Patel
    • Uttar Pradesh
      • Lucknow, Uttar Pradesh, 인도, 226003
        • 모병
        • Charak Hospital and Research Centre
        • 연락하다:
          • Sakshi Jain
    • Uttarakhand
      • Dehradun, Uttarakhand, 인도, 248001
        • 모병
        • Shri Guru Ram Rai Medical College and Shri Mahant Indiresh Hospital
        • 연락하다:
          • Gaurav Shekhar Sharma
    • West Bengal
      • Kolkata, West Bengal, 인도, 700107
        • 모병
        • Fortis Hospital
        • 연락하다:
          • Upal Sengupta
      • Siliguri, West Bengal, 인도, 734012
        • 모병
        • North Bengal Medical College & Hospital
        • 연락하다:
          • Arpita Ray Chaudhury
    • Australian Capital Territory
      • Garran, Australian Capital Territory, 호주, 2605
        • 모병
        • The Canberra Hospital
        • 연락하다:
          • Girish Talaulikar
    • New South Wales
      • Kingswood, New South Wales, 호주, 2747
        • 모병
        • Nepean Blue Mountains Local Health District
        • 연락하다:
          • Bhadran Bose
      • Kogarah, New South Wales, 호주, 2217
        • 모병
        • St George Hospital
        • 연락하다:
          • Sunil Badve
      • New Lambton Heights, New South Wales, 호주, 2305
        • 모병
        • John Hunter Hospital
        • 연락하다:
          • Bobby Chacko
      • Westmead, New South Wales, 호주, 2145
        • 모병
        • Westmead Hospital
        • 연락하다:
          • Vincent Lee
    • Queensland
      • Birtinya, Queensland, 호주, 4575
        • 모병
        • Sunshine Coast Hospital and Health Service
        • 연락하다:
          • Nicholas Gray
      • Douglas, Queensland, 호주, 4814
        • 모병
        • Townsville University Hospital
        • 연락하다:
          • Vikas Srivastava
      • Ipswich, Queensland, 호주, 4305
        • 모병
        • West Moreton Hospital & Health Service
        • 연락하다:
          • Sree Venuthurupalli
      • Southport, Queensland, 호주, 4215
        • 모병
        • Gold Coast Hospital and Health Service
        • 연락하다:
          • Jagadeesh Kurtkoti
    • South Australia
      • Adelaide, South Australia, 호주, 5000
        • 모병
        • Royal Adelaide
        • 연락하다:
          • Michael Collins
      • Elizabeth Vale, South Australia, 호주, 5112
        • 모병
        • Lyell McEwin Hospital
        • 연락하다:
          • Nitesh Rao
    • Victoria
      • Heidelberg, Victoria, 호주, 3084
        • 모병
        • Austin Health
        • 연락하다:
          • Sharon Ford
    • Western Australia
      • Murdoch, Western Australia, 호주, 6150
        • 모병
        • South Metropolitan Health Service, Fiona Stanley Hospital
        • 연락하다:
          • Suda Swaminathan

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Known chronic kidney disease from any cause (eGFR ≥25 mL/min/1.73m2)
  3. Currently receiving standard of care treatment according to treating physician
  4. Eligible for randomisation in at least one recruiting domain-specific appendix
  5. Participant and treating physician are willing and able to perform trial procedures

Exclusion Criteria:

  1. Planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months
  2. Life expectancy less than 6 months

To be included in any of the following DOMAINS the participant must met eligible for the PLATFORM (as listed above)

MRA domain

Inclusion Criteria:

  1. Urine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine protein-creatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening.
  2. On a stable standard of care treatment for CKD, including a SGLT2i unless there is a documented reason not to be using a SGLT2i*, for 4 weeks before screening according to treating physician.
  3. Treating physician believes finerenone is clinically appropriate for the participant.
  4. Participant and treating physician are willing and able to perform MRA DSA procedures.
  5. Provision of written informed consent or eConsent following a fully informed discussion and prior to performing any MRA DSA related procedures

Exclusion Criteria:

  1. Recipient of kidney transplant
  2. Hyperkalaemia (serum potassium ≥5.0 mmol/L) at time of screening
  3. Current treatment with MRA, where the treating physician or patient is not willing to discontinue this medication. If willing to discontinue the MRA, the potential participant must be re-screened after they have been on stable standard of care treatment for 4 weeks without the MRA.
  4. Known allergy, intolerance or contraindication to MRAs
  5. Current treatment with strong CYP3A4 inhibitors
  6. Systolic BP <110 mmHg or diastolic BP<55 mmHg without antihypertensive therapy at time of screening
  7. Severe hepatic impairment (defined as Child-Pugh Class C)
  8. Adrenal insufficiency
  9. Currently pregnant or breast feeding, or intending to become pregnant

GLP-1 RA Domain

Inclusion Criteria

  1. Urine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine proteincreatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening.
  2. On a stable standard of care treatment for CKD, including a SGLT2i and maximum tolerated ACEi/ARB unless there is a documented reason not to be using a SGLT2i, for 4 weeks before screening.
  3. HbA1c less than or equal to 10% (less than or equal to 86mmol/L)
  4. BMI ≥23 kg/m2 and < 50 kg/m2
  5. Treating physician believes semaglutide is clinically appropriate for the participant
  6. Participant and treating physician are willing and able to perform GLP-1 RA DSA procedures
  7. Provision of written informed consent or eConsent following a fully informed discussion and prior to performing any GLP-1 RA DSA related procedures

Exclusion Criteria

  1. Recipient of kidney transplant
  2. Major adverse cardiovascular events (MACE), consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death, within 90 days prior to the day of screening
  3. Presently classified as being in New York Heart Association (NYHA) Class IV heart failure
  4. Personal or first-degree relative(s) with a history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC)
  5. Previous episode of pancreatitis
  6. Uncontrolled thyroid disease TSH>6.0 mIU/L or <0.4mlU/L
  7. Type 1 diabetes
  8. Current treatment with a GLP-1 RA, where it is in the participant's best interests to continue the GLP-1 RA or where the treating physician or patient is not willing to discontinue this medication for a minimum of 4 weeks prior to randomisation and for the full duration of the trial (ie. 108 weeks if assigned to placebo).
  9. Known allergy, intolerance, or contraindication to GLP-1 RAs
  10. Currently pregnant or breast feeding, or intending to become pregnant or is of child-bearing potential, and not using a highly effective contraceptive method
  11. Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 요인 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Finerenone

Finerenone 10mg or 20mg tablets

Finerenone 10mg or 20mg tablets, oral, once daily

다른 이름들:
  • BAY94-8862
위약 비교기: Placebo Finerenone

Finerenone matched placebo tablets

Finerenone matched placebo tablets, oral, once daily

실험적: Semaglutide

Semaglutide 1.0 mg or 2.4 mg pen injector

Semaglutide 1.0mg or 2.4mg pen injector, subcutaneous injection, once weekly

위약 비교기: Placebo Semaglutide

Semaglutide matched placebo pen injector

Semaglutide matched pen injector, subcutaneous injection, once weekly

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Core Primary Outcome Measure
기간: From randomisation to week 108

The primary outcome is chronic eGFR slope. Chronic eGFR slope measures the rate of eGFR decline while on treatment. The duration of time over which chronic eGFR slope is computed can vary by domain and is determined by clinical considerations such as whether the investigational product can cause an acute decline in eGFR upon initiation. DSAs will specify the duration of time over which chronic eGFR slope is computed for the individual domain.

From randomisation to week 108
MRA Domain Primary Outcome Measure
기간: From week 4 to week 108

Chronic eGFR slope estimated from all available eGFR values from week 4 to the end of treatment. The final eGFR value that contributes to the primary outcome is the last eGFR measured while the participant is on treatment.

From week 4 to week 108
GLP1-RA Domain Primary Outcome Measure
기간: From week 0 to week 108

Chronic eGFR slope estimated from all available eGFR values from Week 0 to the end of treatment. The final eGFR value that contributes to the primary outcome is the last eGFR measured while the participant is on treatment.

From week 0 to week 108

2차 결과 측정

결과 측정
측정값 설명
기간
Core Protocol Secondary outcomes
기간: week 0 and 24 weeks

1. Change in albuminuria as measured by uACR (or uPCR if uACR unavailable) between week 0 and 24 weeks, measured as a continuous variable.

week 0 and 24 weeks
Core Protocol Secondary outcomes
기간: week 0 to end of washout

2. eGFR slope from week 0 to end of washout

week 0 to end of washout
Core Protocol Secondary outcomes
기간: week 0 to end of washout

3. Change in eGFR from week 0 to end of washout

week 0 to end of washout
Core Protocol Secondary outcomes
기간: between week 0 and 108 weeks

4. Composite outcome of proportion of participants experiencing a ≥40% eGFR decline between week 0 and 108 weeks, and proportion of participants developing kidney failure (defined as eGFR <15 mL/min/1.73m2 or chronic kidney replacement therapy start†) at 108 weeks.

between week 0 and 108 weeks
Core Protocol Secondary outcomes
기간: from start of study drug (week 0) to washout (week 108) or kidney failure

5. Time to a composite outcome of ≥40% eGFR decline from week 0 or kidney failure

from start of study drug (week 0) to washout (week 108) or kidney failure
Core Protocol Secondary outcomes
기간: at 108 weeks

6. All-cause mortality at 108 weeks

at 108 weeks
Core Protocol Secondary outcomes
기간: between week 0 and week 108

7. Proportion of participants experiencing one or more cardiovascular events (cardiovascular death, hospitalised heart failure, myocardial infarction, stroke)* between week 0 and week 108

between week 0 and week 108
Core Protocol Secondary outcomes
기간: from start of study drug (week 0) to end of washout (week 108)

8. Time to first occurrence of a cardiovascular event

from start of study drug (week 0) to end of washout (week 108)
Core Protocol Secondary outcomes
기간: from start of study drug (week 0) to end of treatment (up to week 104)

9. Safety and tolerability of treatment

from start of study drug (week 0) to end of treatment (up to week 104)
Core Protocol Secondary outcomes
기간: 6-monthly intervals from randomisation to week 108

10. Change in quality of life measured using the Quality of Life Impact Survey for Kidney Disease (QDISCKD) at 6-monthly intervals from randomisation to week 108.

6-monthly intervals from randomisation to week 108
MRA Domain Secondary Outcome
기간: from start of study drug (week 0) to end of washout (week 108)

MRA DSA has a domain-specific secondary outcome that evaluates the time to the composite of ≥57% eGFR decline from week 0 or kidney failure

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
기간: from start of study drug (week 0) to end of washout (week 108)

1. Change in eGFR slope from Week 0 to Week 108.

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
기간: from start of study drug (week 0) to end of washout (week 108)

2. Time to composite of onset of kidney failure (initiation of long-term dialysis, kidney transplantation, or a reduction in the eGFR to <15 mL per minute per 1.73 m2 sustained for ≥28 days), a sustained (for ≥28 days) 50% or greater reduction in eGFR from Week 0, or death from kidney-related or cardiovascular causes.

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
기간: from Week 0 to Week 108

3. Time to first occurrence of onset of persistent ≥50% reduction in eGFR from Week 0 to Week 108

from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
기간: from start of study drug (week 0) to end of washout (week 108)

4. Time to first occurrence of a composite outcome of major adverse cardiovascular events (MACE) consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
기간: from start of study drug (week 0) to end of washout (week 108)

5. Time to occurrence of all-cause death

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
기간: from Week 0 to Week 108

6. Change in body weight from Week 0 to Week 108

from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
기간: Week 0 to Week 108

7. Change in HbA1c from Week 0 to Week 108

Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
기간: from Week 0 to Week 108

8. Change in systolic blood/diastolic blood pressure from Week 0 to Week 108

from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
기간: from Week 0 to Week 108

9. Change in NT-proBNP from Week 0 to Week 108

from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
기간: from randomisation to Week 108

10. Change in health status measured using the 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ) at 6-monthly intervals from randomisation to Week 108

from randomisation to Week 108
GLP-1 RA Domain Secondary Outcome
기간: Week 0 to end of trial

11. Incidence of AEs and the following medical events of special interest (MESI) from Week 0 to end of trial:

  1. Neoplasm (malignant and benign)
  2. Pancreatitis, or persistent abdominal pain leading to a suspicion of pancreatitis
  3. Acute gallstone disease (biliary colic or acute cholecystitis)
  4. Thyroid disease
  5. Cardiac arrhythmia (specifically, atrial fibrillation, atrial flutter, ventricular tachycardia, ventricular fibrillation, torsade de pointes, second degree heart block type 2, third degree heart block, and symptomatic bradycardia requiring pacemaker placement)
  6. Severe hypoglycaemic episodes
  7. Immunogenicity events (allergic reactions, immune-complex disease, and lack of efficacy)
  8. Adverse events leading to treatment discontinuation (if not any of the mentioned MESIs)
  9. Ocular adverse events
  10. Suspicion of transmission of infectious agents
Week 0 to end of trial

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 의자: Sradha Kotwal, The George Institute
  • 연구 의자: Hiddo Lambers Heerspink, The George Institute

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 9월 4일

기본 완료 (추정된)

2029년 12월 31일

연구 완료 (추정된)

2029년 12월 31일

연구 등록 날짜

최초 제출

2023년 9월 21일

QC 기준을 충족하는 최초 제출

2023년 9월 21일

처음 게시됨 (실제)

2023년 9월 28일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 29일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Trial data will be made available as a resource for future unspecified research, subject to any prior contractual obligations. Researchers wishing to gain access to the study resources will be required to submit an application for review by the Platform Oversight Committee, including a detailed project description, a list of data requested, and evidence of ethical approval. De-identified data extracts will be made available to approved proposals, and will not include data obtained from data linkage with local registries.

IPD 공유 기간

TBC

IPD 공유 액세스 기준

Assessments of data requests will be based on sound science, benefit-risk balancing and research team expertise.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다